Metastatic Urothelial Carcinoma Clinical Trials in Irvine, California

3 studies are recruiting for metastatic urothelial carcinoma in Irvine, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

    This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
    Locations
    11 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06439836 on ClinicalTrials.gov

  2. A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

    This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Immunothera…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
    Locations
    161 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06524544 on ClinicalTrials.gov

  3. Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

    The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutraliz…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    COH Lennar, Irvine, California
    Locations
    10 in total
    Run by
    Generate Biomedicines

    See if you can join NCT07484022 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.